Targeting tumor-associated macrophages in cancer therapy and understanding their complexity
Michael A. CannarileRoche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, GermanyCarola H. RiesRoche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, GermanySabine HovesRoche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, GermanyDominik RüttingerRoche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, Germany
2014en
ABI
Abstract
Macrophage infiltration has been identified as an independent, poor prognostic factor for patients afflicted with various cancer entities. However, the characterization of tumor-associated macrophages (TAMs) prior to and following cancer patient treatment has been limited. Our study analyzed tumor biopsies before and after anti-CSF-1R antibody treatment unraveling the nature of TAMs and providing novel insights into their phenotypic and functional characteristics in cancer.
Identifiers
Citations and references
Cited by 20 references